Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more
Transgene SA - Asset Resilience Ratio
Transgene SA (TRGNF) has an Asset Resilience Ratio of 7.32% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2022)
This chart shows how Transgene SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Transgene SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.63 Million | 7.32% |
| Total Liquid Assets | $3.63 Million | 7.32% |
Asset Resilience Insights
- Limited Liquidity: Transgene SA maintains only 7.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Transgene SA Industry Peers by Asset Resilience Ratio
Compare Transgene SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Transgene SA (2010–2022)
The table below shows the annual Asset Resilience Ratio data for Transgene SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 33.75% | $22.42 Million | $66.44 Million | -9.12pp |
| 2021-12-31 | 42.87% | $43.66 Million | $101.84 Million | +18.21pp |
| 2020-12-31 | 24.67% | $21.08 Million | $85.45 Million | -11.73pp |
| 2019-12-31 | 36.40% | $42.03 Million | $115.48 Million | +22.56pp |
| 2018-12-31 | 13.83% | $15.02 Million | $108.54 Million | -25.58pp |
| 2017-12-31 | 39.42% | $39.76 Million | $100.87 Million | -2.35pp |
| 2016-12-31 | 41.77% | $51.35 Million | $122.95 Million | +13.65pp |
| 2015-12-31 | 28.12% | $28.36 Million | $100.87 Million | -16.17pp |
| 2014-12-31 | 44.29% | $62.42 Million | $140.95 Million | +10.34pp |
| 2013-12-31 | 33.95% | $42.72 Million | $125.85 Million | -20.13pp |
| 2012-12-31 | 54.08% | $86.78 Million | $160.46 Million | -17.09pp |
| 2011-12-31 | 71.17% | $137.77 Million | $193.58 Million | -8.82pp |
| 2010-12-31 | 79.99% | $178.92 Million | $223.69 Million | -- |